Literature DB >> 11289481

Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes.

M Emoto1, H Kanda, T Shoji, T Kawagishi, M Komatsu, K Mori, H Tahara, E Ishimura, M Inaba, Y Okuno, Y Nishizawa.   

Abstract

OBJECTIVE: To assess the impacts of insulin resistance and renal function on plasma total homocysteine (tHcy) levels in patients with type 2 diabetes with a wide range of nephropathy. RESEARCH DESIGN AND METHODS: Plasma tHcy levels were measured using the enzyme immunoassay method in 75 patients with type 2 diabetes and compared with those in 54 healthy control subjects. Insulin sensitivity indexes were assessed in patients with type 2 diabetes by hyperinsulinemic-euglycemic clamp using artificial pancreas.
RESULTS: Plasma tHcy levels and their log-translormed values (log tHcy) were significantly higher in all patients with diabetes than in control subjects (tHcy, 12.0 +/- 0.7 [SE] vs. 8.7 +/- 0.3 micromol/l, P < 0.0001; log tHcy, 1.040 +/- 0.021 vs. 0.920 +/- 0.016 micromol/l, P < 0.0001). Plasma tHcy levels in patients with diabetes were significantly increased according to degree of nephropathy (P < 0.0001). On simple regression analyses, log tHcy correlated with insulin sensitivity indexes (r = -0.319, P = 0.005) as well as creatinine clearance (r = 0.634, P < 0.0001) in all patients with diabetes. Multiple regression analyses showed that insulin sensitivity indexes (beta = -0.245) as well as creatinine clearance were independent contributors to log tHcy in all patients with diabetes (R2 = 0.750, P < 0.0001). For the 59 patients with diabetes with creatinine clearance >60 ml/min, insulin sensitivity indexes were also shown to be a significant contributor to log tHcy (beta = -0.438, R2 = 0.561, P < 0.001).
CONCLUSION: Insulin resistance and renal function are independent determinants of tHcy levels in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289481     DOI: 10.2337/diacare.24.3.533

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  20 in total

1.  The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  T Costacou; J C Zgibor; R W Evans; J Otvos; M F Lopes-Virella; R P Tracy; T J Orchard
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

2.  Factors associated with serum total homocysteine level in type 2 diabetes.

Authors:  Yumi Masuda; Akira Kubo; Akatsuki Kokaze; Masao Yoshida; Nobuki Fukuhara; Yutaka Takashima
Journal:  Environ Health Prev Med       Date:  2008-03-29       Impact factor: 3.674

Review 3.  The genetics of vascular complications in diabetes mellitus.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

4.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

5.  Homocysteine levels are associated with the results of 123I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients.

Authors:  Futoshi Anan; Hidetoshi Yonemochi; Takayuki Masaki; Naohiko Takahashi; Mikiko Nakagawa; Nobuoki Eshima; Tetsunori Saikawa; Hironobu Yoshimatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-04       Impact factor: 9.236

6.  High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts.

Authors:  A Solini; E Santini; M Nannipieri; E Ferrannini
Journal:  Diabetologia       Date:  2006-08-01       Impact factor: 10.122

7.  Coronary flow velocity reserve is impaired in hypertensive patients with hyperhomocysteinemia.

Authors:  J Liu; Y Xu; H Zhang; X Gao; H Fan; G Wang
Journal:  J Hum Hypertens       Date:  2014-03-27       Impact factor: 3.012

8.  Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes.

Authors:  H C Looker; A Fagot-Campagna; E W Gunter; C M Pfeiffer; K M Venkat Narayan; W C Knowler; R L Hanson
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

9.  Noninvasive assessment of subclinical atherosclerosis in normotensive gravidae with gestational diabetes.

Authors:  A E Atay; H Simsek; B Demir; M N Sakar; M Kaya; S Pasa; S Demir; D Sit
Journal:  Herz       Date:  2013-07-18       Impact factor: 1.443

10.  Menopause modulates homocysteine levels in diabetic and non-diabetic women.

Authors:  G T Russo; A Di Benedetto; E Alessi; A Giandalia; A Gaudio; R Ientile; K V Horvath; B Asztalos; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.